Iovance Biotherapeutics, Inc. Stock News

Oral Presentation of Updated Results of IOV-COM-202 Cohort 1A of Lifileucel plus Pembrolizumab in Advanced Frontline Melanoma Oral Presentation of Updated Results of IOV-COM-202 Cohort 1A of Lifileuce

Bull markets favor growth stocks, and that means many biotech players could benefit. Wall Street believes in the potential of these two biotech innovators.

Iovance Biotherapeutics has a novel approach to developing cancer medicines. The small biotech recently earned approval for an important product.

Marketbeat's many investor tools include analysts' rankings and sentiment trackers. These tools help investors and traders gauge market sentiment, showing trends and changes, updated revisions, and ne

Iovance Biotherapeutics is experiencing a favorable moment following FDA approval for its melanoma drug Amtagvi and a successful underwritten offering. The company has developed its own production cap

Iovance (IOVA) surges on the recent FDA approval for its lead pipeline drug as the first individualized, one-time cell therapy for certain patients with melanoma.

Both of these companies recently won regulatory approval for their first products. Both Iovance Biotherapeutics and CRISPR Therapeutics have developed game-changing treatment technologies.

The Nasdaq Composite index is up sharply over the past year, but it contains at least two growth stocks poised to run even higher. Investment bank analysts who follow Viking Therapeutics think the sto

Why do you want to consider biotech stocks? Simply, the narrative comes down to numbers and a possible rotation.

Iovance Biotherapeutics is commercializing its first therapy. The product will be fairly expensive to manufacture and distribute.

The FDA removes the clinical hold on Iovance's (IOVA) mid-stage study on LN-145 in certain NSCLC patients after reviewing the company's proposal for additional safety measures and monitoring.

Iovance Biotherapetics recently obtained its first approval from the Food and Drug Administration. The company now has a potential blockbuster on its hands.

Iovance Biotherapetics recently obtained its first approval from the Food and Drug Administration. The company now has a potential blockbuster on its hands.

SAN CARLOS, Calif., March 01, 2024 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), a biotechnology company focused on innovating, developing, and delivering novel polyclonal tumor in

The biotech published its first set of quarterly results after winning an important regulatory nod. Its revenue for the period fell notably short of pundit expectations, however.